东亚药业(605177) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥369,701,875.56, representing a 45.00% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥23,220,016.44, reflecting a 3.38% increase year-over-year[5] - The basic earnings per share remained at ¥0.20, unchanged from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 369,701,875.56, a significant increase of 45% compared to RMB 254,966,058.04 in Q1 2022[19] - The net profit attributable to shareholders for Q1 2023 was CNY 23,220,016.44, compared to CNY 22,461,105.10 in Q1 2022, reflecting an increase of about 3.4%[21] - The company reported a total profit of CNY 26,360,261.89 for Q1 2023, slightly up from CNY 25,854,576.56 in Q1 2022, an increase of about 2.0%[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,510,323,347.67, an increase of 1.58% from the end of the previous year[6] - Total assets as of March 31, 2023, were RMB 2,510,323,347.67, compared to RMB 2,471,356,543.29 at the end of 2022, marking an increase of about 1.6%[17] - Total liabilities increased to RMB 647,314,075.24 from RMB 631,567,287.30, reflecting an increase of approximately 2.8%[17] - Non-current liabilities rose to RMB 84,864,150.76 from RMB 61,876,760.07, representing an increase of about 37%[17] Cash Flow and Working Capital - The net cash flow from operating activities was negative at -¥76,560,280.97, indicating a significant cash outflow[5] - The net cash flow from operating activities for Q1 2023 was negative CNY 76,560,280.97, worsening from negative CNY 14,747,411.47 in Q1 2022[24] - Cash and cash equivalents as of March 31, 2023, amounted to RMB 437,615,919.58, down from RMB 501,581,622.26 at the end of 2022, representing a decrease of approximately 12.7%[15] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 437,615,919.58, down from CNY 497,876,603.38 at the end of Q1 2022, a decrease of about 12.1%[25] - Accounts receivable increased to RMB 185,439,119.64 from RMB 98,453,246.26, reflecting an increase of about 88.3% year-over-year[15] - Inventory decreased to RMB 458,031,512.77 from RMB 482,836,761.74, indicating a reduction of approximately 5.1%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,071[10] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares, totaling 47,116,769 shares[11] - The company’s actual controllers are Chi Zhengming and Chi Cheng, holding a combined 48.33% of the shares[12] Operational Highlights - The increase in revenue was primarily driven by the new production line for cefazolin sodium intermediates, which significantly boosted production and sales compared to last year[9] - The company has not reported any significant new product developments or market expansions during this quarter[13] - The total operating costs for Q1 2023 were CNY 337,139,935.76, an increase from CNY 228,080,537.00 in Q1 2022, representing a growth of approximately 47.9%[20] - Research and development expenses rose to CNY 14,248,858.89 in Q1 2023, up from CNY 8,485,988.91 in Q1 2022, marking a significant increase of approximately 67.5%[20] Non-Recurring Items - Non-recurring gains and losses included a government subsidy of ¥1,462,109.01, contributing positively to the financial results[8] - The company incurred a credit impairment loss of CNY -5,577,518.48 in Q1 2023, compared to CNY -2,159,337.30 in Q1 2022, indicating a deterioration in credit quality[20]